Vaccine Manufacture and Supply

Science writer Anthony King takes a close look at how each of the authorized COVID-19 vaccines are made, and the challenges faced when working to vaccinate the global population.

The transition from manufacturing vaccines in smaller quantities required for academic research to the mass production that is required to protect the global population can be a daunting task. In this article, we discuss key challenges related to the large-scale production of vaccines and also highlight ways to overcome these.

This article covers the challenges associated with conventional vaccine approaches and elaborates on some of the recent innovations which can help design better vaccines.

Technology Networks recently spoke with iBio’s CEO and Chairman of the Board Thomas Isett, to learn more about the company’s efforts to develop a novel COVID-19 therapeutic called ACE2-Fc, as well as two vaccine candidates IBIO-200 and IBIO-201.